- Home
- ACET vs RPTX Comparison
ACET vs RPTX Comparison
Compare ACET & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- RPTX
- Stock Information
- Founded
- ACET 1947
- RPTX 2016
- Country
- ACET United States
- RPTX Canada
- Employees
- ACET N/A
- RPTX N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- ACET Health Care
- RPTX Health Care
- Exchange
- ACET Nasdaq
- RPTX Nasdaq
- Market Cap
- ACET 69.9M
- RPTX 72.6M
- IPO Year
- ACET N/A
- RPTX 2020
- Fundamental
- Price
- ACET $0.81
- RPTX $1.82
- Analyst Decision
- ACET Buy
- RPTX Strong Buy
- Analyst Count
- ACET 4
- RPTX 3
- Target Price
- ACET $5.50
- RPTX $4.50
- AVG Volume (30 Days)
- ACET 1.7M
- RPTX 98.0K
- Earning Date
- ACET 11-05-2025
- RPTX 11-06-2025
- Dividend Yield
- ACET N/A
- RPTX N/A
- EPS Growth
- ACET N/A
- RPTX N/A
- EPS
- ACET N/A
- RPTX N/A
- Revenue
- ACET N/A
- RPTX $250,000.00
- Revenue This Year
- ACET N/A
- RPTX N/A
- Revenue Next Year
- ACET N/A
- RPTX N/A
- P/E Ratio
- ACET N/A
- RPTX N/A
- Revenue Growth
- ACET N/A
- RPTX N/A
- 52 Week Low
- ACET $0.45
- RPTX $0.89
- 52 Week High
- ACET $1.54
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- ACET 49.83
- RPTX 60.62
- Support Level
- ACET $0.79
- RPTX $1.67
- Resistance Level
- ACET $1.03
- RPTX $1.85
- Average True Range (ATR)
- ACET 0.06
- RPTX 0.06
- MACD
- ACET 0.00
- RPTX 0.00
- Stochastic Oscillator
- ACET 18.11
- RPTX 78.38
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.